211 related articles for article (PubMed ID: 18782432)
41. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism.
Liew NC; Alemany GV; Angchaisuksiri P; Bang SM; Choi G; DE Silva DA; Hong JM; Lee L; Li YJ; Rajamoney GN; Suviraj J; Tan TC; Tse E; Teo LT; Visperas J; Wong RS; Lee LH
Int Angiol; 2017 Feb; 36(1):1-20. PubMed ID: 27606807
[TBL] [Abstract][Full Text] [Related]
42. [Venous thromboembolism prophylaxis after general surgery: where are we now?].
Catania G; Di Stefano C; Ippolito G; Minona E; Alongi G; Cardì F
G Chir; 2011 Apr; 32(4):206-10. PubMed ID: 21554853
[TBL] [Abstract][Full Text] [Related]
43. Topical issues in venous thromboembolism.
Abad Rico JI; Llau Pitarch JV; Páramo Fernández JA
Drugs; 2010 Dec; 70 Suppl 2():11-8. PubMed ID: 21162605
[TBL] [Abstract][Full Text] [Related]
44. New anticoagulants in cancer patient treatments.
Arobelidze S; Haddad A; Spiro T; Daw H
Anticancer Drugs; 2016 Oct; 27(9):832-8. PubMed ID: 27387143
[TBL] [Abstract][Full Text] [Related]
45. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
46. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients.
Khorana AA
Oncologist; 2007 Nov; 12(11):1361-70. PubMed ID: 18055857
[TBL] [Abstract][Full Text] [Related]
47. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
Kahn SR; Panju A; Geerts W; Pineo GF; Desjardins L; Turpie AG; Glezer S; Thabane L; Sebaldt RJ;
Thromb Res; 2007; 119(2):145-55. PubMed ID: 16516275
[TBL] [Abstract][Full Text] [Related]
48. [New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application].
Benzidia I; Connault J; Solanilla A; Michon-Pasturel U; Jamelot M; Nguessan MK; Hij A; Le Maignan C; Farge D; Frère C;
J Med Vasc; 2017 Dec; 42(6):375-383. PubMed ID: 29203044
[TBL] [Abstract][Full Text] [Related]
49. Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.
Lyman GH; Kuderer NM
Thromb Res; 2020 Jul; 191 Suppl 1():S79-S84. PubMed ID: 32736784
[TBL] [Abstract][Full Text] [Related]
50. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
51. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.
Greer IA; Nelson-Piercy C
Blood; 2005 Jul; 106(2):401-7. PubMed ID: 15811953
[TBL] [Abstract][Full Text] [Related]
52. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
Nutescu EA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.
Brenner B; Hull R; Arya R; Beyer-Westendorf J; Douketis J; Elalamy I; Imberti D; Zhai Z
Thromb J; 2019; 17():6. PubMed ID: 31011294
[TBL] [Abstract][Full Text] [Related]
54. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature.
Tufano A; Guida A; Di Minno MN; Prisco D; Cerbone AM; Di Minno G
Semin Thromb Hemost; 2011 Apr; 37(3):267-74. PubMed ID: 21455860
[TBL] [Abstract][Full Text] [Related]
55. Venous thromboembolism prophylaxis for the general surgical patient: where do we stand?
Petralia GA; Kakkar AK
Semin Respir Crit Care Med; 2008 Feb; 29(1):83-9. PubMed ID: 18302090
[TBL] [Abstract][Full Text] [Related]
56. International recommendations for the prevention and treatment of venous thromboembolism associated with cancer.
Khosravi-Shahi P; Pérez-Manga G
Clin Drug Investig; 2009; 29(10):625-33. PubMed ID: 19715379
[TBL] [Abstract][Full Text] [Related]
57. Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps.
Steiner D; Ay C
Best Pract Res Clin Haematol; 2022 Mar; 35(1):101347. PubMed ID: 36030066
[TBL] [Abstract][Full Text] [Related]
58. Cancer and venous thromboembolism: prevention, treatment and survival.
Lee AY
J Thromb Thrombolysis; 2008 Feb; 25(1):33-6. PubMed ID: 17906917
[TBL] [Abstract][Full Text] [Related]
59. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
60. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
Dranitsaris G; Shane LG; Woodruff S
J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
